摘要
目的 研究体外构建结核杆菌热休克蛋白和乙型肝炎表面抗原复合物(HSP70-HBsAg)诱导针对乙型肝炎表面抗原特异性免疫反应能力,为该复合物的临床应用奠定基础。 方法 考察体外构建HSP70-HBsAg复合物是否能引起小鼠的体液和细胞免疫;将复合物负载树突状细咆(D C),D C激活同源的T淋巴细胞产生细胞毒性T淋巴细胞(CTL),检测其杀伤HepG2-S细胞的能力。 结果 HSP70-HBsAg复合物能引起小鼠的体液免疫和细胞免疫;HSP70-HBsAg和HBsAg均可诱导CD 81 T淋巴细胞的特异性CTL,而前者的诱导效果更强。 结论 体外构建的HSP70-HBsAg蛋白复合物具有免疫原性,HSP70可以增强抗原蛋白诱导特异性免疫反应的能力,HSP70～HBsAg有望作为蛋白疫苗用于临床慢性乙型肝炎的免疫治疗。
Objective To explore the possibility of cell-medicated immune response induced with heat shock protein 70 (HSP70)-HBsAg protein complex in vitro. Methods HSP70-HBsAg complex was reconstituted in vitro which was injected into mice in order to observe that whether HSP70-HBsAg would stimulate humoral and cellular immune responses. HSP70, HSP70-HBsAg complex and HBsAg were used to activate the dentritic cell (DC) individually, which would initiate homogeneic T lymphocyte to transform to cytotoxic T lymphocyte (CTL). The cytotoxicity of CTL was detected with MTT assay. Results HSP70-HBsAg complex elicited both humoral and cellular immune responses against HBsAg in mice. Specific CD8- CTL response was readily induced by HSP70-HBsAg complex and HBsAg, especially the former. Conclusions HSP70-HBsAg complex is immunogenic and HSP70 can lead to great efficient CTL response. And HSP70-HBsAg complex may be used as a protein vaccine for immunotherapy for chronic hepatitis B.
出处
《中华肝脏病杂志》
CAS
CSCD
2003年第5期271-274,共4页
Chinese Journal of Hepatology
